FARMINGDALE, N.Y.--(BUSINESS WIRE)--Misonix, Inc. (NASDAQ: MSON), a developer of minimally invasive ultrasonic medical device technology, which, in Europe is used for the ablation of cancer and worldwide for other acute health conditions, today announced the expansion of its new sales channel for the United States, which was first disclosed in June 2008. The Company is assembling a team of approximately twenty-five contract sales agents that will sell Misonix labeled product, on a commission only basis, directly to hospitals and clinics throughout the US. The SonicOne™ Wound Management System will be the first product sold by this new sales team. SonicOne is a tissue specific wound cleansing and debridement system, effective for the removal of devitalized or necrotic tissue and fibrin deposits, which ensures progress toward patient healing. Fifteen sales agents are now under contract and have completed training. Exclusive sales territories represented by these fifteen representatives include, among others, major markets such as New York City, Chicago, Houston, Miami, Orlando, New Orleans, Atlanta, Charlotte, and Detroit.
